Why the study?
Does tolfenamic acid improve symptoms in patients with rheumatoid arthritis compared to phenylbutazone or acetylsalicylic acid?
Does tolfenamic acid improve symptoms in patients with rheumatoid arthritis compared to phenylbutazone or acetylsalicylic acid?
Tolfenamic acid is more effective and better tolerated than phenylbutazone or low-dose acetylsalicylic acid in the treatment of rheumatoid arthritis.
Tolfenamic acid merits consideration for rheumatoid arthritis; extends comparative NSAID efficacy data in this RCT.
Sixty patients with diagnosed rheumatoid arthritis were treated at random with tolfenamic acid, a new nonsteroid anti-inflammatory analgesic, in a daily dose of 600 mg, or with phenylbutazone 300 mg or acetylsalicylic acid 1,500 mg daily. Both the patients and the physician found that tolfenamic acid had a clearly better effect than phenylbutazone or the low-dose acetylsalicylic acid used as a control. Tolfenamic acid and acetylsalicylic acid were well tolerated. Serious side-effects (leukopenia and thrombocytopenia in one case, hematemesis and melena in another) only occurred in those patients who received phenylbutazone.
No takes yet. Share an insight, caveat, or question.
Rejholec et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: